SAB Biotherapeutics Inc.

NASDAQ: SABSW · Real-Time Price · USD
0.03
-0.00 (-10.18%)
At close: Apr 29, 2025, 11:53 AM
-10.18%
Bid n/a
Market Cap 278.67K
Revenue (ttm) 1.32M
Net Income (ttm) -34.11M
EPS (ttm) 0.292
PE Ratio (ttm) 0.1
Forward PE n/a
Analyst n/a
Ask n/a
Volume 1,130
Avg. Volume (20D) 22,265.459
Open 0.03
Previous Close 0.03
Day's Range 0.03 - 0.03
52-Week Range 0.03 - 0.03
Beta 0.53

About SABSW

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Mass...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2021
Employees 63
Stock Exchange NASDAQ
Ticker Symbol SABSW
Full Company Profile

Advertisement

No News article available yet